Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V® and Fluad®) in preventing hospitalization for influenza and pneumonia in the elderly: A matched case-control study

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 144-152

  Gasparini, Roberto ^a,b   Amicizia, Daniela ^a,b   Lai, Piero Luigi ^a,b   Rossi, Stefania ^b,c   Panatto, Donatella ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b Inter University Centre for Research on Influenza and Other Transmitted Infections (CIRI IT)   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Adjuvanted vaccines; Elderly; Hospitalization; Influenza; Vaccines

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DRINKING BEHAVIOR; DRUG EFFICACY; EPIDEMIC; FEMALE; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PNEUMOCOCCAL INFECTION; PNEUMONIA; RESPIRATORY TRACT DISEASE; RISK FACTOR; SEASONAL INFLUENZA; SKIN DISEASE; SMOKING; VIRUS ISOLATION; VIRUS STRAIN;

ADJUVANTED VACCINES; ELDERLY; HOSPITALIZATION; INFLUENZA; VACCINES;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ITALY; MALE; PNEUMONIA, VIRAL; VACCINES; VACCINES, VIROSOME;

EID: 84874711999     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22231     Document Type: Article

References (50)

1. Nichol KL. Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy. Vaccine 2009; 27:6305-11; PMID:19840665; http://dx.doi.org/10.1016/j.vaccine.2009.07.006.
2. Nichol KL. Cost-effectiveness and socio-economic aspects of childhood influenza vaccination. Vaccine 2011; 29:7554-8; PMID:21820477; http://dx.doi.org/10.1016/j.vaccine.2011.08.015.
3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; http://dx.doi.org/10.1016/j.vaccine.2007.03.046.
4. Lai PL, Panatto D, Ansaldi F, Canepa P, Amicizia D, Patria AG, et al. Burden of the 1999-2008 seasonal influenza epidemics in Italy: comparison with the H1N1v (A/California/07/09) pandemic. Hum Vaccin 2011; 7(Suppl):217-25; PMID:21922688; http://dx.doi.org/10.4161/hv.7.0.14607.
5. Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, Wei F, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001; 184:665-70; PMID:11517426; http://dx.doi.org/10.1086/ 323085.
6. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the communitydwelling elderly. N Engl J Med 2007; 357:1373-81; PMID:17914038; http://dx.doi.org/10.1056/NEJMoa070844.
7. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al.; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7):1-60; PMID:18685555.
8. World Health Organization. Vaccine use. http://www.who.int/influenza/ vaccines/use/en/
9. Thijs C, Beyer WE, Govaert PM, Sprenger MJ, Dinant GJ, Knottnerus A. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis 2008; 8:460-1, author reply 463-5; PMID:18652989; http://dx.doi.org/10.1016/ S1473-3099(08)70161-0.
10. Chiatti C, Barbadoro P, Lamura G, Pennacchietti L, Di Stanislao F, D'Errico MM, et al. Influenza vaccine uptake among community-dwelling Italian elderly: results from a large cross-sectional study. BMC Public Health 2011; 11:207; PMID:21457562; http://dx.doi.org/10.1186/1471-2458-11-207.
11. Castilla J, Martínez-Artola V, Salcedo E, Martínez-Baz I, Cenoz MG, Guevara M, et al.; Network for Influenza Surveillance in Hospitals of Navarre. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study. Vaccine 2012; 30:195-200; PMID:22100636; http://dx.doi.org/10.1016/j.vaccine.2011.11.024.
12. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:2673-80; PMID:11257408; http://dx.doi.org/10.1016/S0264-410X(00)00499-0.
13. Gasparini R, Lai P, Panatto D. Today's Influenza Vaccines -Why and adjuvant is needed and how it works. European Infectious Disease 2010; 4:36-40.
14. Gasparini R, Pozzi T, Bonanni P, Fragapane E, Montomoli E. Valutazione dei costi di un'epidemia influenzale nella popolazione lavorativa di Siena. Giornale Italiano di Farmacoeconomia 2000; 4:3-9.
15. Gasparini R, Lucioni C, Lai P, Maggioni P, Sticchi L, Durando P et al. Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in Liguria. Pharmacoeconomics -Italian research Articles 2003; 5(Suppl 1):23-30.
16. Tsai TF. MF59 adjuvanted seasonal and pandemic influenza vaccines. Yakugaku Zasshi 2011; 131:1733-41; PMID:22129867; http://dx.doi.org/10.1248/ yakushi.131.1733.
17. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One 2011; 6:e27622; PMID:22110695; http://dx.doi.org/10.1371/journal.pone.0027622.
18. Fisman DN, Tuite AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PLoS One 2011; 6:e27420; PMID:22110645; http://dx.doi.org/10.1371/ journal.pone.0027420.
19. Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 2004; 23:283-9; PMID:15530669; http://dx.doi.org/10.1016/ j.vaccine.2004.07.017.
20. Puig-Barberà J, Díez-Domingo J, Varea AB, Chavarri GS, Rodrigo JA, Hoyos SP, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007; 25:7313-21; PMID:17889411; http://dx.doi.org/10.1016/j.vaccine.2007.08.039.
21. Savulescu C, Valenciano M, de Mateo S, Larrauri A; cycEVA Study Team. Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network-pilot case-control studies using different control groups, 2008-2009 season, Spain. Vaccine 2010; 28:2903-7; PMID:20153351; http://dx.doi.org/10.1016/j.vaccine.2010.01.054.
22. Pregliasco F, Giardini G, Sandrini MC. Efficacia protettiva dell'Inflexal V nel paziente anziano. Vaccine at a glance 2002;1:1-5.
23. Consonni S, Sandrini C, Segato E, Perucchini E, Bergamaschini L, Vergani C. Tolerability and efficacy of anti-influenza vaccination alone and associated with anti-pneumococcal vaccination in an elderly ambulatory population and adherence to the vaccination campaign. J Prev Med Hyg 2004; 45:45-50.
24. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25:3066-9; PMID:17275144; http://dx.doi.org/10.1016/j.vaccine.2007.01.025.
25. Gasparini R. Risultati clinici con il vaccino antinfluenzale adiuvato. Vaccinare oggi 1998; Numero speciale: 41-46.
26. Puig-Barberà J, Márquez-Calderón S, Masoliver-Fores A, Lloria-Paes F, Ortega-Dicha A, Gil-Martín M, et al. Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain. J Epidemiol Community Health 1997; 51:526-30; PMID:9425463; http://dx.doi.org/10.1136/jech. 51.5.526.
27. Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine 2007; 25:154-60; PMID:17064823; http://dx.doi.org/10.1016/j.vaccine.2006.05.129.
28. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270:1956; PMID:8182809; http://dx.doi.org/10.1001/jama.1993.03510160074032.
29. Ahmed AH, Nicholson KG, Nguyen-van Tam JS, Pearson JC. Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic. Epidemiol Infect 1997; 118:27-33; PMID:9042032; http://dx.doi.org/10.1017/ S0950268896007121.
30. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995; 24:1240-8; PMID:8824869; http://dx.doi.org/10.1093/ije/24. 6.1240.
31. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947-52; PMID:7978721.
32. Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, Arden NH, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136:296-307; PMID:1415151.
33. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130:397-403; PMID:10068413.
34. Talbot HK, Griffin MR, Chen Q, Zhu Y, Williams JV, Edwards KM. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011; 203:500-8; PMID:21220776; http://dx.doi.org/10.1093/infdis/jiq076.
35. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123:518-27; PMID:7661497.
36. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20:1831-6; PMID:11906772; http://dx.doi.org/10.1016/S0264-410X(02) 00041-5.
37. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165-74; PMID:16198765; http://dx.doi.org/ 10.1016/S0140-6736(05)67339-4.
38. Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein W, Offit P, eds. Vaccines. Fifth Edition. Philadelphia: Saunders Elsevier, 2008:1259-91.
39. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; CD004876; PMID:20166072.
40. INFLU CIRI. Influenza Surveillance System. Available at http://www.influciri.it
41. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52; PMID:19745214; http://dx.doi.org/10.1056/ NEJMoa0906453.
42. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77; PMID:20687838; http://dx.doi.org/10.1086/655830.
43. Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010; 64:432-8; PMID:20039974; http://dx.doi.org/10.1111/j.1742-1241. 2009.02309.x.
44. Italian Health Ministry. Prevention and control of influenza- recommendations for the 20102011 season. Available at www.salute.gov.it/ influenza/influenza.jsp.
45. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:1000-9; PMID:12660947; http://dx.doi.org/10.1086/368163.
46. Demografie in cifre. Available at http://demo.istat.it/pop2010/index.html
47. Gasparini R, Amicizia D, Lai PL, Panatto D. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Hum Vaccin Immunother 2012; 8:21-8; PMID:22252007.
48. Lai PL, Panatto D, Gasparini R. A pharmacoeconomic appraisal of the strategy to tackle the H1N1v (A/California/07/09) pandemic in Italy: relevance of the CIRI-IV surveillance system. J Prev Med Hyg 2011; 52:142-3; PMID:22010545.
49. Kleinbaum DG, Klein M. Logistic Regression. A Self-Learning Text, Second edition. In: Statistics for Biology and Health. New York, Springer Publishing, 2002:1-59.
50. Rothman KJ, Greenland S, Lash TL. Modern epidemiology, Second Edition. Philadelphia, PA. Lippincott Williams & Wilkins Publishing, 2008:111-28.